ACTN4 and hepatocellular carcinoma: In hepatocellular carcinoma, TRIP13 regulated by miR-192-5p was shown to interact with and increase the expression of actinin alpha 4 (ACTN4), thus activating the AKT/mammalian target of rapamycin (mTOR) pathway to drive tumor progression [26].